AzTrials
AzTrials

HealthyEarly Phase 1NCT06602492

Compensatory Behavior of E-cig Users in Response to Reduced Nicotine E-liquids

A Early Phase 1 study testing Lower nicotine e-liquid and Higher nicotine eliquid in people with Healthy and Nicotine Addiction, run by Rochester Institute of Technology at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn if low nicotine eliquids work to reduce exposure to nicotine, in addicted ecig users, without increasing consumption of other harmful constituents. Read more about this study

Who is it for?
Ages 21 years and older
What is being tested?
Lower nicotine e-liquid and Higher nicotine eliquid
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
72 participants
Where
1 siteUnited States
Study dates
15 Jul 2021to 15 Nov 2023
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 21 years or older
  • Regular 30-day e-cig users

Who cannot join

  • Intention to quit using e-cigs within the next 30 days
  • Use of other tobacco products in addition to e-cigs on more than 9 of the previous 30 days
  • History of acute or chronic asthma
  • Previous diagnosis of cancer
  • Other chronic medical conditions
  • Use of chronic prescription medications
Show all 11Show fewer
  • Pneumonia in prior six weeks
  • Upper respiratory tract infection or other febrile illness in previous 2 weeks
  • Smokers on antioxidants, or anti-inflammatory therapy
  • Pregnant women or women who intend to become pregnant or breast-feeding
  • Had Covid-19 in the past 2 months or still feeling effects from a Covid-19 illness

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Rochester Institute of Technology

    Rochester, New York, 14623

Other trials in United States

About this study

The goal of this clinical trial is to learn if low nicotine eliquids work to reduce exposure to nicotine, in addicted ecig users, without increasing consumption of other harmful constituents.

The main questions it aims to answer are:

Read more
  • Does switching to lower nicotine eliquids change the vaping behavior of addicted ecig users?
  • Does switching to lower nicotine eliquids reduce the amount of nicotine consumed? Researchers will compare ecig users who switch from a higher to lower nicotine eliquid to a control group that does not switch.

Participants will:

  • Complete history of tobacco use and nicotine addiction questionnaires
  • Switch from higher to lower nicotine product or control for 15 days
  • Complete daily questionnaires to report craving, mood and nicotine withdraw

For one full day under each nicotine condition, participants will:

  • record puffing behavior using a topography monitor
  • wear a sensorized shirt that measures the depth and duration of inhalation, and
  • collect a saliva sample at the end of each day
Read the detailed description

This project will investigate whether and how e-cig users compensate puff topography, lung inhalation, and cumulative consumption in response to reduced nicotine eliquid. The project is conducted in the natural environment to objectively measure if users adapt their behavior to maintain their desired level of nicotine.

The project employs a novel behavior-based exposure model that leverages the unique abilities of the investigative team to objectively capture real world behavior. The study employs a novel wPUM™ monitor to record puffing topography and a sensorized shirt to record respiratory parameters for every vaping session.

This study is conducted in the natural environment over 17 days. We will recruit N=80 current established adult ecig users, currently using eliquids with nicotine strengths greater than or equal to 5%, with no intention to quit e-cig use, and no use of combustible or other tobacco products. Participants will be randomized by age, gender, usual brand nicotine strength, and nicotine dependence score into a control arm (non-switching) and a test arm (switching). All participants will be baselined with 5% Juul ecigs and Juul pods containing Virginia Tobacco at 5% nicotine strength. The test arm will be switched to a 3% Juul pods containing Virginia Tobacco at 3% nicotine strength eliquid, while the control arm will continue to use 5% nicotine strength.

Participants will use the RIT wPUM monitor with a Juul ecig and a wearable sensorized garment to record their e-cigarette use topography and inhalation behavior ad-lib in their natural environment at the baseline and intervention conditions for one day each. Biosamples for nicotine exposure in saliva, NNAL in urine and CO will be collected, along with questionnaires to assess product use, compliance, and psychosocial outcomes such as craving, withdrawal and positive/negative emotional state.

Aim 1. Quantify changes in Total Particulate Matter (TPM) exposure among e-cig users adapting to low nicotine eliquids through compensatory changes in puffing, inhalation, and consumption behavior.

TPM exposure will be quantified in the natural environment by recording the topography (puff flow rate, duration, volume) of every puff taken along with respiratory behavior (inhalation/exhalation volume and time and breath hold). This novel outcome measure of exposure is used as a proxy to indicate the impact of behavior on increasing harm potential. We will test hypothesis (H1) that upon changing to a lower nicotine eliquid, users will adapt their behavior (i.e. increase breath hold, adjust puff flow rate, etc.), and in doing so will increase their TPM exposure.

Aim 2. Quantify changes in salivary among e-cig users adapting to low nicotine eliquids.

Salivary cotinine will be measured as a proxy to indicate efficacy of compensatory behavior. A Generalized Linear Mixed-Effects Model (GLME) analysis will be used to investigate how the ability of users to compensate for low nicotine e-liquids is affected by the presence of random effects including sex, age, nicotine dependence score, usual brand nicotine strength, and subjective effects including craving, withdrawal symptoms, and positive/negative emotional state. We will test the hypothesis (H2) that users are able to maintain desired nicotine levels while using a lower nicotine eliquid.

Relationship to Tobacco Regulation: Knowledge gained will support development of effective tobacco product regulations by informing three research questions of regulatory interest: (a) Will limiting the eliquid nicotine concentration reduce harm at the population level? (b) Is there evidence of compensatory behavior exhibited by e-cig users in response to reduced nicotine concentration, and (c) Can we conduct meaningful behavior-based e-cig use risk assessment at the individual level?

Being tested
Lower nicotine e-liquid, Higher nicotine eliquid
Keywords
reduced nicotine eliquid, reduced exposure, cessation
Medical subject headings
Tobacco Use Disorder, Vaping

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lower nicotine e-liquidDrug

    A 3% nicotine concentration eliquid.

  • Higher nicotine eliquidDrug

    A 5% nicotine concentration eliquid.

Study groups in NCT06602492
Study groupRoleWhat they receive
Switching Arm: High to Low NicotineActive comparatorBaselined with a high nicotine eliquid and switched to a low nicotine eliquid.
Receives: Drug: Lower nicotine e-liquid
Control Arm: High to High NicotinePlacebo comparatorBaselined with a high nicotine eliquid and continue with the same high nicotine eliquid.
Receives: Drug: Higher nicotine eliquid

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in the Total Particular Mass (TPM) exposure when switching from the baseline to the intervention condition (high to low nicotine), based on the novel behavior-based yield model.

    A behavior-based yield model, which combines product emissions with real-world user topography, is used to estimate the Change in Cumulative TPM exposure between low and high nicotine products.

    Total Particulate Mass (TPM) exposure of nicotine or other Harmful and Potentially Harmful Constituents (HPHCs) increases as a joint function of (1) the TPM delivered from the e-cig to the mouth, (2) the volume of diluting 'clean air' inhaled with the e-cig puff, and (3) the duration of time the emissions are in the lung.

    TPM exposure is proportional to the product of the TPM, which is the particulate mass contained in each puff delivered to the mouth (quantified by recording the volume of every puff and measuring the associated mass concentration in the emissions), v-inhale, which is the volume of air and entrained ecig aerosol inhaled into the lung with each puff (quantified with a senorized shirt), and t-cycle, which is the total time for the user to inhale each puff, hold their breath an

    Measured: From enrollment to the end of 17 days.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Sep 2024
  2. Study start15 Jul 2021
  3. Primary completion15 Nov 2023
  4. Study completion15 Nov 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
72 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06602492
Sponsor's protocol ID
1R21DA050852
Status last verified
Sep 2024
First submitted
15 Sep 2024
Last updated
27 Sep 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Lower nicotine e-liquid and Higher nicotine eliquid in people with Healthy and Nicotine Addiction, run by Rochester Institute of Technology at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Sep 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in the Total Particular Mass (TPM) exposure when switching from the baseline to the intervention condition (high to low nicotine), based on the novel behavior-based yield model. (time frame: From enrollment to the end of 17 days.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Sep 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT06602492 | AzTrials